ARS Pharmaceuticals, Inc. 8-KCurrent Reports (8-K / ad hoc)

Properties

Item 2.02 Results of Operations and Financial Condition. On August 13, 2026, ARS Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2026 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or subject to the liabilities of that, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933 (the “Securities Act”), whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.